30. April 2021 Start of COVID-19 vaccine production in Reinbek

After fast-trackingthe necessary preparations, Dermapharm today officially began manufacturing BioNTech's Comirnaty®vaccine at Allergopharma's Reinbek facility. Dr Hans-Georg Feldmeier, Dermapharm's CEO, welcomed Federal Minister of Health Jens Spahn, Minister-President Daniel Günther and Minister Dr Heiner Garg at the ceremony. Dermapharm invested in manufacturing the formulation of mRNA active ingredients enveloped by lipid nanoparticles at Allergopharma's state-of-the-art facility. Approximately 40–50 million vaccine doses will be manufactured per month and then transferred to other locations in the BioNTech SE/Pfizer network to be filled in to vials.

"Our specialist know-how in manufacturing pharmaceuticals, especially as it relates to lipid nanoparticles, forms the basis of our cooperation agreement with BioNTech SE. In October 2020, we began manufacturing the Comirnaty®vaccine at mibe GmbH Arzneimittel in Brehna. We successfully applied the expertise we gained from this to Allergopharma's facility. We are very pleased to announce that, as of today, we will be supporting BioNTech/Pfizer in manufacturing the vaccine at two sites, thereby significantly expanding our vital role in beating back the COVID-19 pandemic," said Dr Feldmeier.

Dermapharm is taking on the great responsibility of manufacturing the vaccine. In doing so, the Group has also gained a great deal of expertise that will no doubt be of enormous significance for its future development. In 2020, Dermapharm demonstrated the great feats it is capable of achieving not only by successfully realising the technologically extremely demanding and important vaccine project, but also by improving the entire Group's performance. The location advantages that Germany offers in this regard are key. The COVID-19 pandemic has shown us in dramatic fashion that the ability to deliver is the most important criterion for a successful pharmaceuticals company and has underscored the necessity of maintaining production capacities for pharmaceuticals in Germany and Europe.

Dermapharm acquired Allergopharma on 1 April 2020 and fully consolidated the company into the Group by the end of 2020, which will allow Dermapharm to optimally tapthe enormous potential of Allergopharma and its highly attractive portfolio of products. Allergopharma has more than 50 years' of experience in researching and developing therapies for treating allergies. Allergopharma specialises in subcutaneous hyposensitisation and is one of Europe's market leaders in this field, offering a wide product range with high-dosage, hypoallergenic preparations, known as allergoids. The portfolio also includes a large selection of allergens for diagnostic testing. Allergopharma currently markets its products in ten countries. The company uses its own sales force and external partners to market its products abroad. Allergopharma employed a staff of 320 by the end of the year.